You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.
The work suggests mass spec can more accurately assess levels of immunotherapy targets like PD-L1 than conventional clinical approaches.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
A proteogenomic analysis by a Moffitt Cancer Center-led team uncovered three subtypes of squamous cell lung cancer and treatment approaches to investigate.
The DoD and VA-led initiative is moving beyond its initial focus on lung cancer to add analyses of multiple cancer types and a prospective, multisite study.
The firm also aims to commercialize a new version of its PraediCare Dx platform, which will directly detect heterodimer protein complexes on a tumor cell's surface.